Xin Sun, Wei Guo
Orthopedic Oncology, Peking University People's Hospital, No.11, Xizhimen South Street, Xicheng District, Beijing 100044, China.
J Bone Oncol. 2020 Feb 21;21:100281. doi: 10.1016/j.jbo.2020.100281. eCollection 2020 Apr.
A consensus has not yet been reached regarding the abilities of gender, age, tumor size, tumor location, histologic subtypes, and surgery in the prediction of survival in osteosarcoma. We aimed to disclose their prognostic significance by conducting a meta-analysis of all the published data from the last decade.
Electronic database searches were conducted in PubMed, Embase, and Web of Science for relevant articles published within the last ten years. The pooled hazard ratio (HR) and corresponding 95% confidence interval (CI) were obtained to evaluate the prognostic values of the target factors.
A total of 18,126 patients from 40 studies were eventually included. Results indicated that gender (male vs. female: 1.21, 95% CI, 1.11-1.32; female vs. male: 0.85, 95% CI, 0.75-0.98), age (12-20 vs. ≤12: 1.37, 95% CI, 1.13-1.65; ≥20 vs. <20: 1.29, 95% CI, 1.08-1.55; ≥40 vs. <40: 1.63, 95% CI, 1.21-2.20; ≥50 vs. <25: 2.60, 95% CI, 1.92-3.53; ≥60 vs. <60: 1.11, 95% CI, 1.06-1.18), tumor location (non-extremities vs. extremities: 2.10, 95% CI, 1.76-2.51; proximal vs. distal femur: 3.68, 95% CI: 1.51-8.96; proximal vs. distal humerus: 3.15, 95% CI: 1.53-6.49), tumor size (≥5 vs. <5: 1.42, 95% CI, 1.09-1.86; >8 vs. ≤8: 1.55, 95% CI, 1.07-2.24; >9 vs. ≤9: 1.44, 95% CI, 1.05-1.96), chemotherapy response (poor vs. good: 2.45, 95% CI, 2.02-2.97; good vs. poor: 0.41, 95% CI, 0.34-0.48), and surgery (yes vs. no: 0.45, 95% CI, 0.36-0.57; amputation vs. salvage: 2.34, 95% CI, 1.47-3.74) were significantly associated with overall survival in osteosarcoma patients.
The meta-analysis demonstrated that male patients, older age, large tumor size, non-extremity osteosarcoma, proximal osteosarcoma, poor chemotherapy response, no surgical treatment, and amputation surgery were correlated with a poor prognosis in osteosarcoma patients.
关于性别、年龄、肿瘤大小、肿瘤位置、组织学亚型及手术在骨肉瘤生存预测方面的能力,尚未达成共识。我们旨在通过对过去十年所有已发表数据进行荟萃分析,揭示它们的预后意义。
在PubMed、Embase和Web of Science中进行电子数据库检索,查找过去十年内发表的相关文章。获得合并风险比(HR)及相应的95%置信区间(CI),以评估目标因素的预后价值。
最终纳入了来自40项研究的18126例患者。结果表明,性别(男性vs.女性:1.21,95%CI,1.11 - 1.32;女性vs.男性:0.85,95%CI,0.75 - 0.98)、年龄(12 - 20岁vs.≤12岁:1.37,95%CI,1.13 - 1.65;≥20岁vs.<20岁:1.29,95%CI,1.08 - 1.55;≥40岁vs.<40岁:1.63,95%CI,1.21 - 2.20;≥50岁vs.<25岁:2.60,95%CI,1.92 - 3.53;≥60岁vs.<60岁:1.11,95%CI,1.06 - 1.18)、肿瘤位置(非四肢vs.四肢:2.10,95%CI,1.76 - 2.51;股骨近端vs.远端:3.68,95%CI:1.51 - 8.96;肱骨近端vs.远端:3.15,95%CI:1.53 - 6.49)、肿瘤大小(≥5cm vs.<5cm:1.42,95%CI,1.09 - 1.86;>8cm vs.≤8cm:1.55,95%CI,1.07 - 2.24;>9cm vs.≤9cm:1.44,95%CI,1.05 - 1.96)、化疗反应(差vs.好:2.45,95%CI,2.02 - 2.97;好vs.差:0.41,95%CI,0.34 - 0.48)以及手术(是vs.否:0.45,95%CI,0.36 - 0.57;截肢vs.保肢:2.34,95%CI,1.47 - 3.74)与骨肉瘤患者的总生存期显著相关。
荟萃分析表明,男性患者、年龄较大、肿瘤体积大、非四肢骨肉瘤、近端骨肉瘤、化疗反应差、未接受手术治疗以及截肢手术与骨肉瘤患者预后不良相关。